311 related articles for article (PubMed ID: 9614361)
1. The effects of recombinant human IGF-I administration on concentrations of acid labile subunit, IGF binding protein-3, IGF-I, IGF-II and proteolysis of IGF binding protein-3 in adolescents with insulin-dependent diabetes mellitus.
Cheetham TD; Holly JM; Baxter RC; Meadows K; Jones J; Taylor AM; Dunger DB
J Endocrinol; 1998 Apr; 157(1):81-7. PubMed ID: 9614361
[TBL] [Abstract][Full Text] [Related]
2. The effects of recombinant human insulin-like growth factor-I (IGF-I) administration on the levels of IGF-I, IGF-II and IGF-binding proteins in adolescents with insulin-dependent diabetes mellitus.
Cheetham TD; Taylor A; Holly JM; Clayton K; Cwyfan-Hughes S; Dunger DB
J Endocrinol; 1994 Aug; 142(2):367-74. PubMed ID: 7523562
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment.
Carroll PV; Umpleby M; Alexander EL; Egel VA; Callison KV; Sönksen PH; Russell-Jones DL
Clin Endocrinol (Oxf); 1998 Dec; 49(6):739-46. PubMed ID: 10209561
[TBL] [Abstract][Full Text] [Related]
4. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
[TBL] [Abstract][Full Text] [Related]
5. The differential regulation of the circulating levels of the insulin-like growth factors and their binding proteins (IGFBP) 1, 2 and 3 after elective abdominal surgery.
Cotterill AM; Mendel P; Holly JM; Timmins AG; Camacho-Hübner C; Hughes SC; Ross RM; Blum WF; Langford RM
Clin Endocrinol (Oxf); 1996 Jan; 44(1):91-101. PubMed ID: 8706300
[TBL] [Abstract][Full Text] [Related]
6. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system.
Thrailkill K; Quattrin T; Baker L; Litton J; Dwigun K; Rearson M; Poppenheimer M; Kotlovker D; Giltinan D; Gesundheit N; Martha P
J Clin Endocrinol Metab; 1997 Apr; 82(4):1181-7. PubMed ID: 9100593
[TBL] [Abstract][Full Text] [Related]
7. Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes.
Clemmons DR; Sleevi M; Allan G; Sommer A
J Clin Endocrinol Metab; 2007 Jul; 92(7):2652-8. PubMed ID: 17426090
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes.
Saukkonen T; Amin R; Williams RM; Fox C; Yuen KC; White MA; Umpleby AM; Acerini CL; Dunger DB
J Clin Endocrinol Metab; 2004 Sep; 89(9):4634-41. PubMed ID: 15356074
[TBL] [Abstract][Full Text] [Related]
9. Growth and insulin-like growth factors (IGFs) in children with insulin-dependent diabetes mellitus at the onset of disease: evidence for normal growth, age dependency of the IGF system alterations, and presence of a small (approximately 18-kilodalton) IGF-binding protein-3 fragment in serum.
Cianfarani S; Bonfanti R; Bitti ML; Germani D; Boemi S; Chiumello G; Boscherini B
J Clin Endocrinol Metab; 2000 Nov; 85(11):4162-7. PubMed ID: 11095448
[TBL] [Abstract][Full Text] [Related]
10. Serum insulin-like growth factor II levels in normal adolescents and those with insulin dependent diabetes mellitus.
Acerini CL; Clayton KL; Hintz R; Baker B; Watts A; Holly JM; Dunger DB
Clin Endocrinol (Oxf); 1996 Jul; 45(1):13-9. PubMed ID: 8796133
[TBL] [Abstract][Full Text] [Related]
11. The composition and distribution of insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) in the serum of growth hormone receptor-deficient patients: effects of IGF-I therapy on IGFBP-3.
Gargosky SE; Wilson KF; Fielder PJ; Vaccarello MA; Guevara-Aguirre J; Diamond FB; Baxter RC; Rosenbloom AL; Rosenfeld RG
J Clin Endocrinol Metab; 1993 Dec; 77(6):1683-9. PubMed ID: 7505289
[TBL] [Abstract][Full Text] [Related]
12. Differential long-term effects of insulin-like growth factor-I (IGF-I) growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysectomized rats.
Fielder PJ; Mortensen DL; Mallet P; Carlsson B; Baxter RC; Clark RG
Endocrinology; 1996 May; 137(5):1913-20. PubMed ID: 8612531
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the components of insulin-like growth factor (IGF)-IGF binding protein (IGFBP) system in adolescents with type 1 diabetes and persistent microalbuminuria: relationship with increased urinary excretion of IGFBP-3 18 kD N-terminal fragment.
Spagnoli A; Chiarelli F; Vorwerk P; Boscherini B; Rosenfeld RG
Clin Endocrinol (Oxf); 1999 Nov; 51(5):587-96. PubMed ID: 10594519
[TBL] [Abstract][Full Text] [Related]
14. Response of insulin-like growth factor (IGF)-binding protein-1 (IGFBP-1) and IGFBP-3 to IGF-I treatment in severe insulin resistance.
Quin JD; Checkley A; Gallagher A; Jones J; MacCuish AC; Miell JP
J Endocrinol; 1994 Apr; 141(1):177-82. PubMed ID: 7516962
[TBL] [Abstract][Full Text] [Related]
15. Novel markers to detect recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
Holt RI; Guha N; Böhning W; Bartlett C; Cowan DA; Sönksen PH; Böhning D
Drug Test Anal; 2017 Jan; 9(1):30-37. PubMed ID: 26888146
[TBL] [Abstract][Full Text] [Related]
16. The effects of recombinant human insulin-like growth factor I on growth hormone secretion in adolescents with insulin dependent diabetes mellitus.
Cheetham TD; Clayton KL; Taylor AM; Holly J; Matthews DR; Dunger DB
Clin Endocrinol (Oxf); 1994 Apr; 40(4):515-22. PubMed ID: 8187319
[TBL] [Abstract][Full Text] [Related]
17. Immunoblot studies of the acid-labile subunit (ALS) in biological fluids, normal human serum and in children with GH deficiency and GH receptor deficiency before and after long-term therapy with GH or IGF-I respectively.
Labarta JI; Gargosky SE; Simpson DM; Lee PD; Argente J; Guevara-Aguirre J; Rosenfeld RG
Clin Endocrinol (Oxf); 1997 Dec; 47(6):657-66. PubMed ID: 9497872
[TBL] [Abstract][Full Text] [Related]
18. Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
Guha N; Erotokritou-Mulligan I; Nevitt SP; Francis M; Bartlett C; Cowan DA; Bassett EE; Sönksen PH; Holt RI
Drug Test Anal; 2013; 5(11-12):843-9. PubMed ID: 24173773
[TBL] [Abstract][Full Text] [Related]
19. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study.
Boonen S; Rosen C; Bouillon R; Sommer A; McKay M; Rosen D; Adams S; Broos P; Lenaerts J; Raus J; Vanderschueren D; Geusens P
J Clin Endocrinol Metab; 2002 Apr; 87(4):1593-9. PubMed ID: 11932288
[TBL] [Abstract][Full Text] [Related]
20. Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans.
Lieberman SA; Bukar J; Chen SA; Celniker AC; Compton PG; Cook J; Albu J; Perlman AJ; Hoffman AR
J Clin Endocrinol Metab; 1992 Jul; 75(1):30-6. PubMed ID: 1377706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
